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Abstract: Background and Objectives: Intrahepatic cholangiocarcinoma (iCCA) is a pernicious tumor
characterized by a dismal outcome and scarce therapeutic options. To substantially improve the
prognosis of iCCA patients, a better understanding of the molecular mechanisms responsible for
development and progression of this disease is imperative. In the present study, we aimed at
elucidating the role of the maternal embryonic leucine zipper kinase (MELK) protooncogene in
iCCA. Materials and Methods: We analyzed the expression of MELK and two putative targets,
Forkhead Box M1 (FOXM1) and Enhancer of Zeste Homolog 2 (EZH2), in a collection of human
iCCA by real-time RT-PCR and immunohistochemistry (IHC). The effects on iCCA growth of both
the multi-kinase inhibitor OTSSP167 and specific small-interfering RNA (siRNA) against MELK were
investigated in iCCA cell lines. Results: Expression of MELK was significantly higher in tumors than
in corresponding non-neoplastic liver counterparts, with highest levels of MELK being associated
with patients’ shorter survival length. In vitro, OTSSP167 suppressed the growth of iCCA cell lines in a
dose-dependent manner by reducing proliferation and inducing apoptosis. These effects were amplified
when OTSSP167 administration was coupled to the DNA-damaging agent doxorubicin. Similar results,
but less remarkable, were obtained when MELK was silenced by specific siRNA in the same cells. At the
molecular level, siRNA against MELK triggered downregulation of MELK and its targets. Finally, we
found that MELK is a downstream target of the E2F1 transcription factor. Conclusion: Our results indicate
that MELK is ubiquitously overexpressed in iCCA, where it may represent a prognostic indicator and a
therapeutic target. In particular, the combination of OTSSP167 (or other, more specific MELK inhibitors)
with DNA-damaging agents might be a potentially effective therapy for human iCCA.
Keywords: intrahepatic cholangiocarcinoma; MELK; FOXM1; EZH2; targeted therapies
1. Introduction
Cholangiocarcinoma (CCA) is a heterogeneous group of highly aggressive epithelial malignancies
originating at any level of the biliary tract and showing features of cholangiocellular differentiation [1,2].
Over the last few decades, epidemiological studies have revealed a steady increase of incidence and
mortality from intrahepatic CCA (iCCA) globally, probably due to an increase of related risk factors,
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whereas the extrahepatic CCA (eCCA) frequency has slightly declined [3]. The American Cancer
Society (www.cancer.org) reports that the 5-year overall survival rate is approximately 24% for iCCA
and 13% for eCCA, respectively. In early stage CCA, surgical resection and liver transplantation are
the only effective treatment options, yet most of CCA patients are diagnosed at advanced stages [4].
Due to the scarce understanding of CCA molecular pathogenesis, the range of therapeutic options
available for progressed CCA is limited and unsatisfactory [1]. Indeed, the standard first line therapy
for patients with unresectable CCA, consisting of the combined administration of gemcitabine and
platin-based drugs, provides almost negligible benefits [5]. Thus, novel and more effective treatments
against CCA are urgently needed.
Dysregulation of multiple kinases has been described as one of the major mechanisms by
which cancer cells escape normal physiological constraints on proliferation and survival. Maternal
embryonic leucine zipper kinase (MELK), a member of the snf1/AMP protein kinase family of
serine/threonine kinases, activates multiple signaling cascades driving oncogenic growth [6,7]. MELK
is a cell cycle-dependent kinase localized at chromosome 9p 13.2, whose expression is increased in
many tumor tissues and in mitotically blocked cells, indicating that MELK expression is controlled
during cell proliferation [8,9]. Various studies have shown that MELK interacts with a number of
proteins, including the cell cycle protein CDC25B [10], mitogen-activated protein kinase (MAPK) [11],
components of the Bcl-2 family [12], Smad proteins, which are intracellular mediators of the TGF-beta
pathway [13], and TP53 [14]. Unlike other members of the AMPK family, MELK is not directly involved
in the balance of cellular metabolism [7], but rather in cell cycle regulation, proliferation, apoptosis,
and tumor formation [7,15]. MELK may also play a key role in tumor resistance to therapies and DNA
repair, as MELK inhibition significantly increases the sensitivity to radiotherapy and chemotherapy
in various models [16,17]. Thus, it is not surprising that high levels of MELK are detected in many
solid tumors and in leukemia, where increased MELK expression correlates with poor prognosis and
aggressiveness [18–31]. Genomic and pharmacological inhibition of MELK has been shown to hamper
tumor growth, both in vitro and in various preclinical tumor models, further suggesting that this kinase
could be a potential therapeutic target in cancer [22,28,29,32]. Although the molecular mechanisms
whereby MELK induces aggressive tumor growth are not completely understood, it appears clear
that MELK exerts its oncogenic role in association with the Forkhead Box Protein M1 (FOXM1)
protooncogene [33], a master regulator of cell cycle progression that is remarkably activated in several
human cancers, including HCC [21,34]. In the latter tumor type, MELK was found to be highly
overexpressed and correlated to vascular invasion, early recurrence, and poor survival [21].
Moreover, after binding and phosphorylation of FOXM1, the MELK–FOXM1 activated complex
binds to the promoter and induces the transcription of the enhancer of zeste homolog 2 (EZH2)
gene [17,35]. Upregulation of EZH2, a lysine methyltransferase, leads to the transcriptional repression
of genes promoting differentiation, while maintaining stem-like properties of cancer cells [17,24,36].
Some specific pathways containing MELK have been identified in glioblastoma multiforme (GBM),
such as the c-JUN/MELK and MELK/PRC1 cascades, which support the survival of cancer stem
cells (CSCs) [16]. Another study on GBM identified the protein Stathmin as a downstream target
of the MELK pathway involved in the progression of this deadly disease [37]. In addition, a recent
investigation revealed the eukaryotic translation initiation factor 4B (eIF4B) as a substrate of MELK. The
latter is a novel signaling pathway that regulates protein synthesis during mitosis and, consequently,
the survival of cancer cells [38]. Although mounting evidence indicates elevated levels of MELK in
many tumor types, the molecular mechanisms responsible for the unrestrained activity of MELK
remain poorly defined, and reports dealing with its regulation are scanty. A few previous studies
suggested MELK as a downstream effector of the E2F1 transcription factor. Specifically, a genome-wide
profiling of REF52 rat fibroblasts identified MELK as a member of a subset of E2F1 targets responsible
for the anti-apoptotic properties of E2F1. In the same study, the authors also showed that MELK is
upregulated in a subgroup of advanced, highly aggressive ovarian and breast tumors characterized
by E2F1 overexpression [39]. In addition, a putative E2F1 binding site was identified in the MELK
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promoter in MC3T3-E1 mouse osteoblasts [40]. E2F1 is a member of the E2F family of transcription
factors responsible for a plethora of biological functions, including cell cycle progression, apoptosis,
DNA repair, and metabolism, and whose expression is frequently induced in cancer, leading to
unrestrained growth and poor prognosis of the patients [41–43].
In light of these findings, suppression/inactivation of MELK may be an attractive therapeutic
strategy in cancer. Currently, the only designated MELK inhibitor is OTSSP167, an orally administered
drug, which is under evaluation in Phase 1 studies on various tumor types (identifiers: NCT01910545,
NCT02926690, NCT02768519, and NCT02795520; www.clinicaltrials.gov) [44–46]. OTSSP167 binds
to MELK, preventing both its phosphorylation and activation, thus inhibiting the phosphorylation
of downstream MELK substrates [44–46]. It was reported that OTSSP167 reduced tumor burden
in a murine model of multiple myeloma [45,46]. Specifically, OTSSP167 induced potent and rapid
apoptosis of multiple myeloma cells, and impaired outgrowth of malignant plasma cells derived
from myeloma stem cells in the peripheral blood [45,46]. Furthermore, OTSSP167 has been shown to
suppress Sox2 expression in a dose-dependent manner in head and neck squamous cell carcinoma
(HNSCC). Since Sox2 is involved in self renewal and tumorigenicity, MELK inhibition is believed to act
as a key component of CSCs modulator through the regulation of Sox2 [47]. Also, OTSSP167 has been
described as the most potent inhibitor of Human Cytomegalovirus (HCMV) replication in a study
for the identification of already existing kinase inhibitors that can potentially be repurposed as novel
antiviral drugs [48]. Nonetheless, kinobeads profiling and CRISPR/Cas9 mutagenesis studies recently
demonstrated that OTSSP167 is a broad multi-kinase inhibitor. As a consequence of its off-target
activity, the results of these studies undermined and did not support the clinical validation of OTSSP167
as a drug targeting MELK [49,50].
In the present study, we sought to determine the function of MELK in human intrahepatic
cholangiocarcinoma (iCCA) by evaluating the levels of MELK and some of its targets in a collection of
human iCCA and corresponding non-tumorous surrounding livers. Subsequently, we assessed the
effects of MELK modulation on proliferation and apoptosis of iCCA cell lines. Finally, we investigated
the role of E2F1 as an upstream inducer of MELK. Overall, our results indicate that MELK is an E2F1
effector gene potentially important as a prognostic marker and therapeutic target for human iCCA.
2. Materials and Methods
2.1. Human Tissue Samples
Five normal livers (obtained from residual liver tissues of liver donors), 52 iCCA, and corresponding
surrounding non-tumor liver tissues were used for the study. Patients’ clinicopathological features
are summarized in Table 1. Survival data were available for 39 patients. Liver tissues were collected
at the Universities of Sassari (Sassari, Italy) and Greifswald (Greifswald, Germany). Institutional
Review Board approval was obtained at local Ethical Committees of the Medical Universities of Sassari
(approval code: 2377/CE; 31 May 2016) and Greifswald (approval code: BB 67/10; 3 June 2010), in
compliance with the Helsinki Declaration. Written informed consent was obtained from all individuals.
Table 1. Clinicopathological features of intrahepatic cholangiocarcinoma (iCCA) patients.
Variables
No. of patients; male; female 52; 31; 21
Age (years); <60; >60 14; 38
Etiology; HBV; HCV; hepatolithiasis; PSC; NA 12; 7; 12; 3; 18
Liver cirrhosis; yes; no 20; 32
Tumor differentiation; well; moderately; poorly 24; 20; 8
Tumor size (cm); <5; >5 36; 16
Tumor number; single; multiple 38; 14
Lymph node metastases; yes; no; NA 19; 21; 12
Abbreviations: NA, not available; PSC, primary sclerosing cholangitis.
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2.2. Histology and Immunohistochemistry
Human liver specimens were fixed overnight in 4% paraformaldehyde and embedded in paraffin.
Sections were done at 5 µm in thickness. Liver lesions were assessed by two board-certified pathologists
and liver experts (S.R. and F.D.). For immunohistochemical staining, slides were deparaffinized in
xylene, rehydrated through a graded alcohol series, and rinsed in PBS. Antigen retrieval was performed
either in 10 mM sodium citrate buffer (pH 6.0) by placement in a microwave oven on high for 10 min,
followed by a 20-min cool down at room temperature. After a blocking step with the 5% goat serum
and Avidin-Biotin blocking kit (Vector Laboratories, Burlingame, CA, USA), the slides were incubated
with the rabbit polyclonal anti-MELK (# HPA017214; Sigma-Aldrich, St. Louis, MO, USA; dilution
1:200), the rabbit monoclonal anti-EZH2 (# 5246; Cell Signaling Technology (Danvers, MA, USA);
dilution 1:100), and the rabbit monoclonal anti-CK19 (# 12434; Cell Signaling Technology; 1:500)
primary antibodies overnight at 4 ◦C. Slides were then subjected to 3% hydrogen peroxide for 10 min to
quench endogenous peroxidase activity and, subsequently, the biotin conjugated secondary antibody
was applied at a 1:500 dilution for 30 min at room temperature. The immunoreactivity was visualized
with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) and Vector NovaRed
(Vector Laboratories) as the chromogen. Slides were counterstained with hematoxylin.
2.3. Quantitative Reverse Transcription Real-Time Polymerase Chain Reaction (qRT-PCR)
Gene Expression Assays for humanMELK (ID# Hs01106438_m1), FOXM1 (Hs01073586_m1), EZH2
(Hs00544830_m1), E2F1 (ID # Hs00153451_m1), and β-Actin (ID # 4333762T) genes were purchased
from Applied Biosystems (Foster City, CA, USA). Quantitative values for each gene were calculated by
using the PE Biosystems Analysis software and expressed as number target (NT). NT = 2−∆Ct, wherein
∆Ct value of each sample was calculated by subtracting the average Ct value of the target gene from
the average Ct value of the β-Actin gene.
2.4. In Vitro Experiments
Mycoplasma-free, HUCCT1, and HUH28 human iCCA cell lines, after validation (Genetica DNA
Laboratories, Burlington, NC, USA), were used for the in vitro studies. The two cell lines were kindly
provided by Prof. Xin Chen (University of California San Francisco, San Francisco, CA, USA). Cell
lines were maintained as monolayer cultures in Dulbecco’s modified Eagle medium supplemented
with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA), 100 U/mL penicillin, and 100 g/mL
streptomycin (Gibco, Grand Island, NY, USA). Cells were grown for 12 h, then serum-deprived for 24 h
and treated with siRNA against MELK (# S386; ThermoFisher Scientific) or E2F1 (# S4405; ThermoFisher
Scientific), following the manufacturer’s recommendations. In addition, HUCCT1 and HUH28 cells
were seeded in 24-well plates and treated with the non-selective MELK inhibitor OTSSP167 (Selleck
Chemicals, Houston, TX, USA) at 40 and 100 nM concentration for 24–48 h. For the induction of DNA
damage, cells were treated with 2 µmol/L doxorubicin (Sigma-Aldrich, St. Louis, MO, USA) for 2 h,
washed twice with phosphate-buffered saline (PBS), and returned to normal growth medium for the
indicated time periods. Cell proliferation was assessed in the cell lines at 24- and 48-h time points using
the BrdU Cell Proliferation Assay Kit (Cell Signaling Technology, Danvers, MA, USA). As concerns
apoptosis, it was determined in the two iCCA cell lines using the Cell Death Detection Elisa plus Kit
(Roche Molecular Biochemicals, Indianapolis, IN, USA), following the manufacturer’ instructions.
Cells were initially subjected to 24 h serum starvation. Subsequently, apoptotic cell death was assessed
at 24- and 48-h time points. Finally, to assess DNA damage of cultured HCC cells, the DNA Damage
Quantification Kit (Biovision, Mountain View, CA, USA) was applied following the manufacturer’s
instructions, and results were recorded at 24- and 48-h time points. All cell line experiments were
repeated at least three times in triplicate.
Medicina 2020, 56, 1 5 of 16
2.5. Statistical and Bioinformatic Analysis
GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, CA, USA) was used to evaluate
statistical significance by Tukey–Kramer, Student’s t, and Mann–Whitney tests and linear regression
analyses. Values of p < 0.05 were considered significant. Data are expressed as mean ± standard
deviation for each group. Two-tailed unpaired t-test was used to compare the differences between
two groups.
E2F1 putative transcription factor binding motifs on MELK gene promoters were predicted using
the Eukaryotic Promoter Database New (EPDnew; https://epd.epfl.ch) that combines EPD promoters
with promoter-specific high-throughput data [51].
3. Results
3.1. Overexpression of MELK in Human Intrahepatic Cholangiocarcinoma
First, we investigated the mRNA levels of MELK gene by real-time RT-PCR in an iCCA
collection (n = 52; Table 1). Strikingly, significantly higher MELK mRNA levels when compared
with corresponding non-tumorous counterparts (ST) and normal livers (NL) were detected (Figure 1A).
A similar trend of expression was detected when assessing the levels of two canonical MELK targets,
namely Forkhead Box Protein M1 (FOXM1; Figure 1B) and Enhancer of Zeste Homolog 2 (EZH2; Figure 1C)
genes. Consequently, a significant correlation between the mRNA levels of MELK and those of FOXM1
and EZH2 was observed (Figure 1D–F). Subsequently, to further substantiate our data, we assessed
the protein levels of MELK and EZH2 by way of immunohistochemistry in the same iCCA collection.
In normal healthy liver and non-tumorous surrounding liver tissues, low cytoplasmic and weak or
absent nuclear immunolabeling for MELK was observed (Figure 2). Faint nuclear immunolocalization
for the EZH2 protein was detected in the same tissues. In striking contrast and in agreement with
real-time RT-PCR data, we found a strong cytoplasmic and/or nuclear immunoreactivity for MELK
and EZH2 proteins in iCCA (Figure 3).
Figure 1. MELK and its downstream effectors are overexpressed in human intrahepatic
cholangiocarcinoma (iCCA) specimens. (A–C) Quantitative real-time RT-PCR analysis of MELK,
FOXM1, and EZH2 mRNA levels in normal livers (n = 5), iCCA (n = 52), and corresponding
non-tumorous surrounding liver tissues (ST; n = 52). Quantitative values were calculated by using
the PE Biosystems Analysis software and expressed as number target (N Target). N Target = 2−∆Ct,
wherein the ∆Ct value of each sample was calculated by subtracting the average Ct value of the gene of
interest from the average Ct value of the β-Actin gene. p-value was calculated using Mann–Whitney U
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test. * p < 0.01 when compared to Normal Liver (NL); ** p < 0.001 when compared to Normal liver
(NL) and Surrounding Tissue (ST). Abbreviation: NS, not significant. (D–F) Expression levels of MELK,
FOXM1, and EZH2 correlate with each other in human iCCA samples.
Figure 2. Representative immunohistochemical patterns of MELK and EZH2 proteins in human
non-tumorous surrounding tumor tissues. A non-neoplastic portion of liver tissue in the proximity of
one intrahepatic cholangiocarcinoma is displayed at two magnifications (100×, upper panels; 200×,
lower panels) and shows weak cytoplasmic and nuclear staining of hepatocytes for MELK and EZH2
proteins, respectively. Low to moderate immunoreactivity for MELK and EZH2 in biliary epithelial
cell is indicated by arrows. An equivalent staining pattern for MELK and EZH2 characterized normal
healthy liver tissues (not shown). The CK19 staining was used as a marker of biliary differentiation of
the tumors. Scale bar: 100 µm. Abbreviation: H&E, hematoxylin and eosin staining.
Figure 3. Representative immunohistochemical patterns of MELK and EZH2 proteins in human
intrahepatic cholangiocarcinoma specimens (iCCA). A cholangiocellular tumor (T) is shown at two
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magnifications (100×, upper panels; 200×, lower panels) and exhibits concomitantly strong cytoplasmic
and/or nuclear staining for MELK and EZH2 proteins, whereas weak/absent immunoreactivity is
displayed by the non-tumorous surrounding counterpart (ST). The CK19 staining was used as a marker
of biliary differentiation of the tumors. Scale bar: 100 µm. Abbreviation: H&E, hematoxylin and
eosin staining.
Overall, these concordant findings indicate the simultaneous upregulation of MELK and its targets
(FOXM1 and EZH2) in human iCCA specimens.
3.2. MELK is a Negative Prognostic Indicator in Intrahepatic Cholangiocarcinoma
To determine a possible prognostic role of MELK in this tumor type, levels of MELK mRNA
in iCCA were related to the length of survival of the patients. Survival data were available for 39
of the 52 patients examined. Noticeably, we found that higher MELK gene expression correlates
with lower iCCA survival rate, as assessed both by Kaplan–Meier and linear regression analysis
(p < 0.0001; Figure 4A,D). This association remained strongly significant after multivariate Cox
regression analysis (p < 0.0001; Supplementary Materials), thus indicating that MELK mRNA levels
represent an independent prognostic factor for iCCA. Equivalent results were observed when assessing
the correlation between FOXM1 (Figure 4B,E) or EZH2 (Figure 4C,F) expression and the length of
patients’ survival using the same statistical tools. No association between the levels of MELK mRNA
and clinicopathologic features of iCCA patients, including age, gender, etiology, presence of cirrhosis,
tumor size, and tumor differentiation, was detected (Supplementary Materials).
Figure 4. MELK, FOXM1, and EZH2 levels correlate with an adverse outcome in human intrahepatic
cholangiocarcinoma (iCCA). (A–C) Kaplan–Meier survival curves of human iCCA with high and low
MELK, FOXM1, and EZH2 mRNA levels, showing the unfavorable outcome of patients with elevated
expression of the three genes. (D–F) Linear regression analysis showing a statistically significant,
inverse correlation between the levels of MELK, FOXM1, and EZH2, and the length (months) of
patients’ survival.
Taken together, the present findings indicate that induction of the MELK gene is almost universal
in human iCCA, where MELK overexpression predicts poor outcome for iCCA patients.
3.3. Suppression of MELK is Highly Detrimental for the Growth of Human iCCA Cell Lines
Subsequently, we evaluated the effects of MELK suppression on the growth of iCCA. For this
purpose, we assessed the growth inhibitory activity of the MELK non-selective inhibitor OTSSP167 on
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human iCCA cell lines. The HUCCT1 and HuH28 iCCA cell lines were selected for the experiments
(Figure 5). At the cellular level, OTSSP167 resulted in decreased proliferation and rise of apoptosis in
the two cell lines in a dose-dependent manner. Due to the established role of MELK in promoting DNA
repair and genome integrity [16,17], we hypothesized that cancer cells depleted of MELK might be more
vulnerable to DNA insults than the corresponding cells retaining MELK activity. To test this hypothesis,
the two iCCA cell lines were subjected to OTSSP167 treatment in association with doxorubicin, a DNA
damaging agent. Strikingly, an impressive growth restraint, elevated apoptosis, and massive DNA
damage were detected in HUCCT1 and HuH28 cells when administration of OTSSP167 was coupled
to treatment with doxorubicin. At the molecular level, treatment with OTSSP167 did not affect MELK
mRNA levels in HUCCT1 and HuH28 cell lines, in accordance with the notion that OPSSP167 impairs
MELK activity but not its expression (Figure 6) [44]. In contrast, downregulation of FOXM1 and
EZH2 gene expression was detected following OTSSP167 administration in both cell lines. Of note,
doxorubicin treatment induced the upregulation of MELK, FOXM1, and EZH2 genes, in accordance
with the role of MELK in the DNA repair response (Figure 6) [16,17].
Next, to exclude possible off-target effects of OTSSP167 [44,45], the HUCCT1 and HUH28 cell
lines were subjected to MELK knockdown using specific small interfering RNA (siRNA) against MELK
(Figure 7). Silencing of MELK resulted in slight decrease of proliferation and induction apoptosis in the
two iCCA cell lines. Similar to that described for the OTSSP167 treatment (although less pronounced),
a strong growth reduction and generation of DNA damage was induced when combining doxorubicin
administration to MELK knockdown. As expected, at the molecular level (Figure 8), treatment with
MELK siRNA resulted in the downregulation of MELK and its downstream effectors, FOXM1 and
EZH2.
Figure 5. Effect of inhibition of MELK by the non-selective inhibitor OTSSP167, either alone or in
association with doxorubicin administration (DOXO) on proliferation (A; OD 450 nm), apoptosis (B;
OD 405 nm), and DNA damage (C; absolute number of apurinic sites per 105 base pairs) of HUCCT1
and HUH28 intrahepatic cholangiocarcinoma (iCCA) cell lines. Data are means ± standard deviation
(SD) of three experiments conducted in triplicate. Tukey–Kramer test: At least p < 0.01; a, vs. control
(untreated cells); b, vs. DMSO (solvent); c, vs. OTSSP167 40 nM; d, vs. OTSSP167 100 nM; e, vs. DOXO.
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Figure 6. Effect of inhibition of MELK activity by the non-selective inhibitor OTSSP167, either alone or
in association with doxorubicin administration (DOXO) on the levels of MELK, FOXM1, and EZH2
mRNA in HUCCT1 (A) and HUH28 (B) human intrahepatic cholangiocarcinoma (iCCA) cell lines.
Data are means ± SD of three experiments conducted in triplicate. Tukey–Kramer test: At least p < 0.01;
a, vs. control (untreated cells); b, vs. DMSO (solvent); c, vs. OTSSP167 40 nM; d, vs. OTSSP167 100 nM;
e, vs. DOXO.
Figure 7. Effect of inhibition of MELK expression by the specific siRNA against MELK, either alone or
association with doxorubicin administration (DOXO) on proliferation (A; OD 450 nm), apoptosis (B; OD
405 nm), and DNA damage (C; absolute number of apurinic sites per 105 base pairs) of HUCCT1 and
HUH28 intrahepatic cholangiocarcinoma (iCCA) cell lines. Data are means ± SD of three experiments
conducted in triplicate. Tukey–Kramer test: At least p < 0.01; a, vs. control (untreated cells); b, vs.
scramble siRNA; c, vs. MELK siRNA; d, vs. DOXO.
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Figure 8. Effect of inhibition of MELK expression by the specific siRNA against MELK, either alone
or association with doxorubicin administration (DOXO) on the levels of MELK, FOXM1, and EZH2
mRNA in HUCCT1 (A) and HUH28 (B) human intrahepatic cholangiocarcinoma (iCCA) cell lines.
Tukey–Kramer test: At least p < 0.001; a, vs. control (untreated cells); b, vs. scramble siRNA; c, vs.
MELK siRNA; d, vs. DOXO.
Altogether, the present data indicate that suppression of MELK significantly constrains the growth
of iCCA cell lines in vitro, especially in association with DNA damaging agents.
3.4. MELK Is a Transcriptional Target of the E2F1 Protooncogene in Intrahepatic Cholangiocarcinoma
Finally, we sought to determine whether MELK is a downstream effector of the E2F1 transcription
factor in iCCA. Several approaches were employed for this purpose. First, we performed an in silico
prediction of the binding sites for E2F1 on MELK gene promoter using the EPDnew software [51].
Noticeably, we identified two putative binding sites for E2F1 on the MELK gene promoter region
(p < 0.01; Figure 9A), situated −119 and +81 from the ATG starting codon. Next, E2F1 was knocked
down in the HUCCT1 and HUH28 cell lines by specific siRNA. As expected, siRNA-mediated silencing
of E2F1 resulted in both cell lines in a marked downregulation of MELK, further substantiating the
hypothesis of MELK being a transcriptional target of E2F1 (Figure 9B,C). Subsequently, we examined
whether a correlation between MELK and E2F1 mRNA levels exist in our iCCA collection. The trend of
E2F1 gene expression in the iCCA collection closely recapitulated that of MELK, with highest levels
being detected in iCCA and lower levels in normal livers and non-tumorous surrounding livers.
No significant differences were observed between the last two entities (Figure 9D). As a consequence,
a strong direct correlation between the levels of the two transcription factors was found (Figure 9E).
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Figure 9. E2F1 is an upstream inducer of MELK in human intrahepatic cholangiocarcinoma (iCCA)
cell lines. (A) In silico prediction of E2F1 binding sites on the MELK gene promoter using a cut-off of
p-value of 0.001. Binding sites are represented in red squares. The EPDnew software was used for this
scope. (B) Inhibition of E2F1 expression (left panel) by the specific siRNA against E2F1 induces the
downregulation of MELK mRNA levels (right panel) in the HUCCT1 cell line. (C) Inhibition of E2F1
expression (left panel) by the specific siRNA against E2F1 triggers the downregulation of MELK mRNA
levels (right panel) in the HUH28 cell line. Data are means ± SD of three experiments conducted in
triplicate. Tukey–Kramer test: At least p < 0.001; a, vs. control (untreated cells); b, vs. scramble siRNA.
(D) Quantitative real-time RT-PCR analysis of E2F1 mRNA levels in normal livers (n = 5), iCCA (n
= 52), and corresponding non-tumorous surrounding liver tissues (ST; n = 52). Quantitative values
were calculated by using the PE Biosystems Analysis software and expressed as number target (N
Target). N Target = 2−∆Ct, wherein the ∆Ct value of each sample was calculated by subtracting the
average Ct value of E2F1 gene from the average Ct value of the β-Actin gene. p-value was calculated
using Mann–Whitney U test. ** p < 0.001 when compared to ST; * p < 0.01 when compared with NL.
Abbreviation: NS, not significant. (E) Expression levels of E2F1 and MELK correlate with each other in
human iCCA samples.
Overall, the present results identify E2F1 as an upstream inducer of MELK in iCCA.
4. Discussion
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal tumor, characterized by rising incidence,
clinical aggressiveness, high recurrence rate, and limited therapeutic options [1–5]. The prognosis
of iCCA patients is most often poor due the late diagnosis of the disease and the lack of effective
treatments when the tumor is unresectable [1–5]. To overcome this gloomy scenario, novel molecular
targets and more effective therapies are urgently needed.
In the present investigation, we focused on the role in cholangiocarcinogenesis of MELK, a gene
frequently activated in a variety of tumor types [6]. We show here that MELK is overexpressed and
possesses oncogenic properties in human iCCA. Indeed, we found a significant upregulation of MELK
and its targets, FOXM1 and EZH2, in iCCA when compared with normal livers and non-tumorous
surrounding livers. These findings suggest that induction of MELK might be involved in liver
malignant transformation. Furthermore, a marked increase of MELK expression was detected in
tumors associated with shorter survival length of the patients, thus underlining a role of MELK also in
iCCA biological aggressiveness and the patient’s prognosis. In agreement with our data, high levels of
MELK have been previously shown to directly correlate with an unfavorable outcome in various cancer
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entities [18–31]. Therefore, overall the present findings strongly support an important pathogenetic
and prognostic role of MELK in human iCCA.
In in vitro experiments, we found that MELK suppression by way of the non-selective inhibitor
OTSSP167 or specific siRNA significantly reduced the proliferation and augmented apoptosis in iCCA
cells, suggesting that MELK contributes to cholangiocarcinogenesis via multiple mechanisms. Of note,
the deleterious effects on cell growth were markedly amplified by the treatment with the DNA-damaging
agent doxorubicin. These data suggest a major function of MELK in protecting the iCCA cells from
DNA damage, in agreement with previous data obtained in glioma cells [16,17,24]. The molecular
mechanisms whereby MELK promotes the DNA repair response remain poorly understood. It has
been previously shown that MELK can bind to and phosphorylate the p53 tumor suppressor [14],
suggesting that MELK properties on preserving the DNA integrity might be p53-dependent. However,
this at least partly does not hold true for iCCA, since both cell lines used in this study (HUCCT1 and
HUH28) harbor mutations in the p53 gene. Further studies are necessary to determine the precise
mechanisms through which MELK contributes to the DNA damage response.
Although both approaches aimed at inhibiting MELK activity (namely OTSSP167 administration
and siRNA-mediated MELK gene silencing) were able to reduce the growth of HUCCT1 and HUH28
cell lines, a stronger anti-neoplastic activity was observed when administering the non-selecting
inhibitor to the cells. Since it has been proven that OTSSP167 does not selectively inhibit MELK [49,50],
we cannot exclude that part of the anti-growth function (s) of OTSSP167 is due to off-target effects of
the drug. In support of the latter hypothesis, a recent investigation showed that OTSSP167 hampers
the proliferation and colony formation ability of lung cancer cell lines, as well as carcinogenesis in
lung cancer xenografts via the suppression of the PAK1 protooncogene [52]. Furthermore, it has been
found that MELK suppression by siRNA did not recapitulate the mitotic effects of OTSSP167 treatment
in MCF7 and Hela cancer cell lines. In these cells, the growth inhibitory activity of the drug in fact
mainly depended on the inhibition of other kinases, such as BUB1 and Haspin [53]. Thus, to address
the functions of MELK in cancer more precisely, either MELK genetically engineered mouse models
and/or selective inhibitors of this protein should be used. In this regard, the small-molecule inhibitor
MELK-T1 has been recently developed [54] and might be highly helpful for this purpose. Nonetheless,
the data obtained in the present study and in many other tumor types support further investigation on
the effectiveness of OTSSP167 as an anticancer drug and underline the importance of ongoing clinical
trials testing this drug in various tumor entities (NCT01910545, NCT02926690, NCT02768519, and
NCT02795520; www.clinicaltrials.gov).
At the molecular level, we identified the E2F1 transcription factor as the upstream inducer of
MELK in iCCA. E2F1 is a major player in various physiological and pathological events, due to its
ability to regulate a wide number of cellular events, including cell cycle, apoptosis, DNA repair, and
metabolism [41–43,55–59]. Of note, the E2F1 transcriptional program is aberrantly activated in the vast
majority of human iCCA due to the inactivation of the retinoblastoma protein (pRb) and is sensitive to
the treatment with CDK4/6 inhibitors such as Palbociclib [60]. Thus, it is possible that MELK represents
a surrogate marker of E2F1 activation in this tumor type and might be helpful to select people to be
treated with CDK4/6 inhibitors.
5. Conclusions
In summary, we revealed that MELK is an E2F1-responsive target presumably playing a crucial
role in human iCCA development and progression. Also, we envisaged the possibility that MELK is a
prognostic marker for this tumor type. Furthermore, we found that the anti-growth effects driven by
MELK inhibition are strongly amplified by the concomitant administration of a DNA damaging agent.
Thus, the administration of MELK inhibitors, together with DNA damaging agents, might represent a
novel and promising therapeutic strategy against human iCCA.
Supplementary Materials: The following are available online at http://www.mdpi.com/1010-660X/56/1/1/s1,
as Supplementary Information in docx file.
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